Monogram Biosciences, Inc. announced that three presentations related to the HERmark Breast Cancer Assay and VeraTag technology will be made at the 45th meeting of the American Society for Clinical Oncology (ASCO) in Orlando.
“Breast cancers are heterogeneous. Tumors express distinct levels of proteins that may impact the therapeutic effectiveness of particular drugs. Even when tumors are defined as ‘HER2-positive’, clinical responses to HER2-target therapies are varied, but it hasn’t been clear what accounts for the observed differences in outcome,” said Michael Bates, M.D. Monogram Vice President of Clinical Research.
“Using the VeraTag technology, we now have clinical data suggesting that precise quantification of HER2 and HER3 expression levels in FFPE specimens allows us to identify multiple sub-populations of patients with HER2-positive metastatic breast cancer that experience different clinical outcomes following treatment with trastuzumab. Taken together, these studies demonstrate the promise of the VeraTag technology to aid in the development of personalized treatment strategies for patients with breast cancer.”